MedTrace Logo

Cholestanol in Humans

NCT00018694 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-10-14

No results posted yet for this study

Summary

The treatment of cerebrotendinous xanthomatosis an in born error of bile acid synthesis with chenodeoxycholic acid. Patients with this disease over produce cholestanol and bile acid precursors because of the block in synthesis. Replacement with chenodeoxycholic acid shut down abnormal pathway and reduces elevated level of cholestanol and improves the clinical syndrome.

Conditions

  • Cerebrotendinous Xanthomatosis

Interventions

DRUG

Chenodeoxycholic Acid

Sponsors & Collaborators

Principal Investigators

  • Gerald Salen · VA New Jersey Health Care System, East Orange

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE

Eligibility

Min Age
5 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00018694 on ClinicalTrials.gov